JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...
24/7 Wall St.

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

France denies contact with Eli Lilly over reported $17.5 bln Abivax deal

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief

Retatrutide's recent trial results suggest it may be even better than Eli Lilly's already approved GLP-1 medication, ...
Barchart on MSN

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...
PharmExec

JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success

Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition ...